Apollomics (APLM)
NASDAQ:APLM
Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$36.16M
Enterprise Value$15.53M
Total Cash (Recent Filing)$9.77M
Total Debt (Recent Filing)$966.00K
Price to Earnings (P/E)1.2
Beta0.49
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-54.48
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue78.46
Enterprise Value/Gross Profit78.46
Enterprise Value/Ebitda-0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Oncology FocusApollomics’ focus on precision oncology and genetically defined cancers is a durable strategic advantage: targeted small-molecule programs can command premium clinical value, enable biomarker-driven trials, and improve partnerability, supporting long-term commercialization pathways if clinical data are positive.
Material Revenue Pickup In 2025A sharp revenue increase in 2025 signals improved commercial or partnering traction and validates aspects of the business model beyond pure R&D. Sustainable revenue generation can reduce future financing needs and supports incremental investment in trials and operations over the medium term.
Low Absolute Debt BurdenVery low reported debt leaves the company less encumbered by fixed interest obligations, preserving capacity to raise capital or negotiate collaborations. For a loss-making biotech, modest leverage reduces near-term bankruptcy risk and gives optionality to pursue development milestones.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow implies ongoing dependence on external financing to fund R&D and trials. That reliance increases dilution and execution risk, constrains long-term planning, and can delay or curtail pivotal studies if funding conditions tighten.
Negative Stockholders' EquityNegative shareholders’ equity reflects accumulated deficits that weaken balance-sheet resilience and heighten financing risk. It can limit borrowing capacity, complicate collaboration negotiations, and signal structural funding needs that persist until sustained profitability is achieved.
Deep And Persistent UnprofitabilityLarge operating losses and absent gross profit despite revenue growth indicate the firm lacks scale or margin capture needed for self-sustaining operations. Continued losses increase the urgency for successful clinical outcomes or partnerships to shift the profit trajectory over the medium term.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $36.16M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 141 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
822.25%
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
0.56% Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---